Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers Webinar Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers Certara2026 年 3 月 9 日
Navigate GxP Compliance in the Cloud with Confidence Guide Navigate GxP Compliance in the Cloud with Confidence Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…Certara2026 年 3 月 6 日
Understanding and Calculating Steady State Pharmacokinetics BlogKnowledge Base Understanding and Calculating Steady State Pharmacokinetics Steady state pharmacokinetics can seem abstract and confusing. Read this blog to gain a better…Certara2026 年 3 月 5 日
Phoenix Roadshow 2026 – Raleigh/Durham Live Events Phoenix Roadshow 2026 – 美国罗利-达勒姆 Certara2026 年 3 月 2 日
Phoenix Roadshow 2026 – Philadelphia Live Events Phoenix Roadshow 2026 – Philadelphia Certara2026 年 2 月 27 日
Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit) On-Demand Webinar Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit) This webinar introduces the Phoenix IVIVC Toolkit, showing how to perform BE analysis and build…Certara2026 年 2 月 27 日
Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Webinar Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Danielle Pillsbury2026 年 2 月 23 日
Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs) Webinar Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs) Certara2026 年 2 月 23 日